Checkmate Pharmaceuticals Obtains $20,000,000 Series A Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=500a8917-3bbb-4e10-83c0-7a963f828786
Date 8/13/2015
Company Name Checkmate Pharmaceuticals
Mailing Address 1 Broadway 14th Floor Cambridge, MA 02142 USA
Company Description Checkmate Pharma is developing a new approach for cancer immunotherapy, by specifically activating the immune system to recognize and kill tumor cells throughout the body, without harming normal tissues. We have exclusively licensed a clinically validated virus-like particle (VLP) platform from Cytos Biotechnology Ltd (SIX:CYTN) for the field of oncology, that includes the clinical product (CYT003) and technologies related to oligonucleotide synthesis and VLP delivery.
Proceeds Purposes These funds will further enable the company to develop additional generations of oligonucleotide-based products in the field of immuno-oncology.